Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of “Moderate Buy” from Analysts

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $22.1250.

Several brokerages have issued reports on CMPS. HC Wainwright upped their price target on shares of Compass Pathways from $40.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Morgan Stanley lifted their price target on shares of Compass Pathways from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Royal Bank Of Canada increased their price objective on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st.

Hedge Funds Weigh In On Compass Pathways

Hedge funds have recently made changes to their positions in the stock. RTW Investments LP lifted its stake in shares of Compass Pathways by 0.6% in the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after acquiring an additional 50,000 shares during the period. Nantahala Capital Management LLC increased its position in Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after purchasing an additional 1,350,698 shares during the period. Millennium Management LLC increased its position in Compass Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after purchasing an additional 774,090 shares during the period. Toronto Dominion Bank raised its holdings in Compass Pathways by 152.9% during the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after purchasing an additional 1,529,013 shares during the last quarter. Finally, ARK Investment Management LLC raised its holdings in Compass Pathways by 1.6% during the 4th quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after purchasing an additional 34,894 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Stock Down 3.6%

Shares of NASDAQ CMPS opened at $6.39 on Friday. The company has a 50 day simple moving average of $6.99 and a 200 day simple moving average of $6.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. Compass Pathways has a 1 year low of $2.25 and a 1 year high of $8.90. The firm has a market cap of $613.55 million, a PE ratio of -2.35 and a beta of 1.90.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.